Published Date: Mar 11 2022
Gene-Biocon has received the "Notice of Approval for Clinical Trials of Insulin Degludec Injection" issued by the State Drug Administration
*Acceptance number: [CXSL2101500]
As one of the leading biopharmaceutical biopharma companies in China, Gene-Biocon has remained true to our original aspiration and escorted customers with continuous innovation. In the future, Gene-Biocon will continue to devote itself to the field of Biopharmaceutical raw materials and cosmetic raw materials, and continue to produce with high-quality and safe products for our customers.